Chronic ischaemic heart disease. Chronic ischaemic heart disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: 150 mg Q10 supplementation will give to individuals in three divided doses (Q10 in capsule form -Iran Drug maker Exir Pharmaceuticals) for 7 days. Intervention 2: C
Treatment - Drugs
Intervention group: 150 mg Q10 supplementation will give to individuals in three divided doses (Q10 in capsule form -Iran Drug maker Exir Pharmaceuticals) for 7 days
Control group: The control group will receive capsules with the same shape, from the same company with no therapeutic content (just the color) ,three times a day for 7 days
Sponsors
Vice Chancellor for research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 80 patients' eligible for CABG surgery; Tehran Heart Hospital Rajai Exclusion criteria: Patients with the following conditions (recent intake of antioxidants either warfarin. (a month) ; Valve replacement; and those with BMI above 30; Kidney disease (cr above 1.5)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of Troponin. Timepoint: Pre-intervention and post-intervention and 24-hour, seven days after surgery. Method of measurement: ELISA Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Levels of CK-MB. Timepoint: Pre-intervention and post-intervention and 24-hour, seven days after surgery. Method of measurement: ELISA Kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJalal Moludi
Department of Clinical Nutrition, School of Nutrition and Dietitics, Tehran University of Medical Sc
Outcome results
None listed